[go: up one dir, main page]

MX2022001947A - Anticuerpos que se unen a las proteinas lrp5 y metodos de uso. - Google Patents

Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.

Info

Publication number
MX2022001947A
MX2022001947A MX2022001947A MX2022001947A MX2022001947A MX 2022001947 A MX2022001947 A MX 2022001947A MX 2022001947 A MX2022001947 A MX 2022001947A MX 2022001947 A MX2022001947 A MX 2022001947A MX 2022001947 A MX2022001947 A MX 2022001947A
Authority
MX
Mexico
Prior art keywords
antibodies
bind
methods
lrp5
lrp5 proteins
Prior art date
Application number
MX2022001947A
Other languages
English (en)
Inventor
Jagath R Junutula
Stephane Angers
Sachdev Sidhu
Guohua Pan
Nish Patel
Jason Moffat
Jarrett Adams
Original Assignee
Modmab Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modmab Therapeutics Inc filed Critical Modmab Therapeutics Inc
Publication of MX2022001947A publication Critical patent/MX2022001947A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

En el presente documento se proporcionan anticuerpos que se unen específicamente a LRP5 y un método de uso de los mismos.
MX2022001947A 2019-08-14 2020-08-14 Anticuerpos que se unen a las proteinas lrp5 y metodos de uso. MX2022001947A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962886913P 2019-08-14 2019-08-14
PCT/CA2020/051119 WO2021026665A1 (en) 2019-08-14 2020-08-14 Antibodies that bind to lrp5 proteins and methods of use

Publications (1)

Publication Number Publication Date
MX2022001947A true MX2022001947A (es) 2022-06-14

Family

ID=74570326

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001947A MX2022001947A (es) 2019-08-14 2020-08-14 Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.

Country Status (10)

Country Link
US (1) US20230183336A1 (es)
EP (1) EP4013791A4 (es)
JP (1) JP2022544308A (es)
KR (1) KR20220078568A (es)
CN (2) CN119798435A (es)
AU (1) AU2020329092A1 (es)
CA (1) CA3147827A1 (es)
IL (1) IL290509A (es)
MX (1) MX2022001947A (es)
WO (1) WO2021026665A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023250402A2 (en) * 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2022212429A1 (en) * 2021-03-31 2022-10-06 Sachdev Sidhu Anti-viral compositions for rift valley fever virus infections and methods of using same
WO2024007008A2 (en) * 2022-06-30 2024-01-04 The University Of Chicago Cd73 (nt5e) targeting polypeptides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
US20070149496A1 (en) * 2003-10-31 2007-06-28 Jack Tuszynski Water-soluble compound
US8790650B2 (en) * 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
IN2014DN05885A (es) * 2012-01-18 2015-06-05 Hoffmann La Roche
US20190194314A1 (en) * 2012-12-21 2019-06-27 Stowers Institute For Medical Research Antibodies for modulating binding between lrp and wise
US10294294B2 (en) * 2015-09-10 2019-05-21 Albert Einstein College Of Medicine Synthetic antibodies to BAX and uses thereof
AR106949A1 (es) * 2015-12-04 2018-03-07 Boehringer Ingelheim Int Polipéptidos biparatópicos que antagonizan la señalización wnt en células tumorales
KR102717656B1 (ko) * 2017-05-31 2024-10-14 베링거 인겔하임 인터내셔날 게엠베하 종양 세포에서 wnt 신호 전달을 길항하는 폴리펩티드
JP6873445B2 (ja) * 2017-10-27 2021-05-19 ニューヨーク ユニバーシティ 抗ガレクチン−９抗体及びその使用
US11746150B2 (en) * 2017-12-19 2023-09-05 Surrozen Operating, Inc. Anti-LRP5/6 antibodies and methods of use
WO2019159084A1 (en) * 2018-02-14 2019-08-22 Angers Stephane Multivalent binding molecules activating wnt signaling and uses thereof
US10640562B2 (en) * 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
EP3844282A4 (en) * 2018-08-29 2022-06-01 Nanjing Legend Biotech Co., Ltd. ANTI-MESOTHELIN CHIMERAL ANTIGEN RECEPTOR (CAR) CONSTRUCTS AND THEIR USES

Also Published As

Publication number Publication date
CN119798435A (zh) 2025-04-11
EP4013791A4 (en) 2024-01-24
AU2020329092A1 (en) 2022-03-31
US20230183336A1 (en) 2023-06-15
WO2021026665A1 (en) 2021-02-18
CN114599679B (zh) 2024-10-18
IL290509A (en) 2022-04-01
EP4013791A1 (en) 2022-06-22
KR20220078568A (ko) 2022-06-10
JP2022544308A (ja) 2022-10-17
CN114599679A (zh) 2022-06-07
CA3147827A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
MX2025000260A (es) Proteina de union al antigeno anti-steap1
MX2021003393A (es) Proteinas de fijacion a sirp alfa y metodos de uso de estas.
PH12018501882A1 (en) Binding proteins and methods of use thereof
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
PH12020551710A1 (en) Anti-hla-g antibodies and use thereof
JOP20200300A1 (ar) أجسام مضادة لـ il-11ra
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
WO2020006374A3 (en) Anti-sirp-beta1 antibodies and methods of use thereof
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
SG10201801219VA (en) Anti-HER2 Antibodies
EA201992460A1 (ru) Антитела-агонисты btla и их применение
MX2022001947A (es) Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
MX2023012300A (es) Anticuerpos humanos contra artemina y metodos de uso de estos.
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
EP4013790A4 (en) ANTIBODIES BINDING TO LRP6 PROTEINS AND METHODS OF USE THEREOF
PH12018501674A1 (en) Anti-citrullinated hla polypeptide antibodies and uses thereof
HK40074168A (en) Antibodies that bind to lrp5 proteins and methods of use
HK40074699A (en) Antibodies that bind to lrp6 proteins and methods of use
EA202092279A1 (ru) Антитела к mica и/или micb и их применение